Citi Lifts HUTCHMED Price Target to HK$43.2 and Names It a New Top Pick

Stock News11-06

Citi released a research report stating that it held an expert meeting with the principal investigator of SANOVO on November 5, further reinforcing its positive view on the potential of savolitinib in first-line and post-osimertinib EGFR-mutant non-small cell lung cancer, maintaining a "Buy/High Risk" rating, naming HUTCHMED (00013) as a new top pick, and raising its target price from HK$40.1 to HK$43.2.

According to the bank, based on strong SAFFRON data, the new drug application for savolitinib has already been submitted in the United States and accepted in Japan and Europe, and HUTCHMED management expects overseas approval possibly in fiscal year 2027; the bank is optimistic about the commercialization outlook and believes savolitinib could become a billion-dollar blockbuster, with further upside remaining in the first-line opportunity.

The bank raised its revenue forecasts for fiscal years 2027 and 2028 by 4% and 2%, and lifted its earnings per share estimates by 15% and 5%, mainly reflecting the potential overseas approval of savolitinib and adjustments to its epidemiological model.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment